183 related articles for article (PubMed ID: 37010714)
21. Systematic profiling of alternative splicing signature reveals prognostic predictor for prostate cancer.
Zhao J; Chang L; Gu X; Liu J; Sun B; Wei X
Cancer Sci; 2020 Aug; 111(8):3020-3031. PubMed ID: 32530556
[TBL] [Abstract][Full Text] [Related]
22. A N
Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
[TBL] [Abstract][Full Text] [Related]
23. A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.
Hu K; Hu X; Duan Y; Li W; Qian J; Chen J
Front Med (Lausanne); 2022; 9():815541. PubMed ID: 35783639
[TBL] [Abstract][Full Text] [Related]
24. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
25. Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma.
Li Y; Yang Z
Pathol Res Pract; 2018 Nov; 214(11):1811-1817. PubMed ID: 30195637
[TBL] [Abstract][Full Text] [Related]
26. Utilizing Ubiquitination Patterns to Predict Prostate Cancer Prognosis and Devise a Therapeutic Response.
Zhang X; Wang Y; Chang Y; Wang J; Yan S; Xiao Y; Guo T; Lou Y; Ma J; Xu W; Ren S
Arch Esp Urol; 2023 May; 76(3):215-231. PubMed ID: 37340527
[TBL] [Abstract][Full Text] [Related]
27. Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma.
Wu ZY; Wang SG; Li Q; Zhao QS; Shao MM
Math Biosci Eng; 2019 Dec; 17(3):2037-2047. PubMed ID: 32233522
[TBL] [Abstract][Full Text] [Related]
28. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
Front Oncol; 2021; 11():778637. PubMed ID: 35004299
[TBL] [Abstract][Full Text] [Related]
29. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
30. Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
AZhaTi B; Wu G; Zhan H; Liang W; Song Z; Lu L; Xie Q
World J Surg Oncol; 2022 Jul; 20(1):231. PubMed ID: 35820925
[TBL] [Abstract][Full Text] [Related]
31. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
32. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
33. Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data.
Huang H; Xu H; Li P; Ye X; Chen W; Chen W; Huang X
Bioengineered; 2021 Dec; 12(1):5504-5515. PubMed ID: 34514952
[TBL] [Abstract][Full Text] [Related]
34. A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.
Ye C; Qin S; Qiu S; Zhao L; Miao J; Chen Y; Zhou T
Transl Androl Urol; 2022 Dec; 11(12):1691-1705. PubMed ID: 36632155
[TBL] [Abstract][Full Text] [Related]
35. Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.
Guo H; Wang S; Xie A; Sun W; Wei C; Xian S; Yin H; Li M; Sun H; Li H; Meng T; Zhang J; Huang Z
Dis Markers; 2021; 2021():1484227. PubMed ID: 34745385
[TBL] [Abstract][Full Text] [Related]
36. tRNA-Derived RNA Fragments Are Novel Biomarkers for Diagnosis, Prognosis, and Tumor Subtypes in Prostate Cancer.
Liu W; Yu M; Cheng S; Zhou X; Li J; Lu Y; Liu P; Ding S
Curr Oncol; 2023 Jan; 30(1):981-999. PubMed ID: 36661724
[TBL] [Abstract][Full Text] [Related]
37. Integrative analysis of cancer driver genes in prostate adenocarcinoma.
Zhao X; Lei Y; Li G; Cheng Y; Yang H; Xie L; Long H; Jiang R
Mol Med Rep; 2019 Apr; 19(4):2707-2715. PubMed ID: 30720096
[TBL] [Abstract][Full Text] [Related]
38. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
Front Genet; 2020; 11():534. PubMed ID: 32595697
[TBL] [Abstract][Full Text] [Related]
39. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
